<DOC>
	<DOCNO>NCT00330746</DOCNO>
	<brief_summary>The purpose study select promise method combine cetuximab gemcitabine treat patient advanced non small-cell lung cancer , candidate platinum base therapy .</brief_summary>
	<brief_title>CALC-1 ( Cetuximab Advanced Lung Cancer ) : Study 2 Methods Combining Cetuximab Gemcitabine Patients With Advanced Non Small-cell Lung Cancer</brief_title>
	<detailed_description>The standard treatment advance non small cell lung cancer ( NSCLC ) combination chemotherapy cisplatin carboplatin . Due toxicity , therapy may suit certain patient include elderly , whose general condition poor . Combining chemotherapy biologic agent ( `` target therapy '' ) new strategy evaluate treatment NSCLC , cetuximab one drug show promise activity tolerability . This study aim determine promise 2 method combine gemcitabine cetuximab ( combination vs. sequential administration ) , two group patient candidate combination platinum base chemotherapy : patient age 70 performance status 2 ( expect enrollment 42 ) , patient age 70 ( expect enrollment 58 ) . Patients randomly assign one two treatment arm : - Arm A : Cetuximab + Gemcitabine : - Cetuximab give intravenously weekly AND - Gemcitabine give intravenously maximum 6 cycle ( day 1 8 3 week cycle ) - Arm B : Gemcitabine follow Cetuximab : - Gemcitabine give intravenously maximum 6 cycle ( day 1 8 3 week cycle ) THEN - Cetuximab give intravenously weekly In Arm B , Cetuximab administer maintenance therapy objective response chemotherapy , second line therapy patient disease progression chemotherapy</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Signed write informed consent Age &gt; 18 Histological diagnosis non smallcell lung cancer ( NSCLC ) Stage III B Stage IV disease Contraindications platinum base therapy ( age &gt; 70 age &lt; 70 ECOG performance status 2 ) At least one site metastasis ( target nontarget ) Life expectancy least 3 month ECOG &lt; 3 Neutrophils &gt; 1500/mm3 , platelet &gt; 100,000/mm3 , hemoglobin &gt; 9g/dl Bilirubin &lt; 1.5 x upper normal limit SGOT SGPT &lt; 2.5 x upper normal limit ( &lt; 5 x upper normal limit presence hepatic metastasis ) Creatinine &lt; 1.5 x upper normal limit Adequate method contraception ( male female ) , risk conception . Symptomatic cerebral metastasis Previous chemotherapy advance disease Adjuvant chemotherapy within previous 6 month Radiation therapy within previous 4 week Any experimental drug therapy within previous 4 week Previous exposure monoclonal antibody , signal transduction inhibitor EGFR target therapy Clinically relevant cardiopathy myocardial infarct within last 12 month Acute subacute intestinal occlusion history inflammatory bowel disease Known allergy one experimental treatment Known alcohol substance abuse Medical psychological condition opinion investigator would permit patient complete study give inform consent Pregnant breastfeeding female History malignant neoplasm within previous 5 year ( include nonmelanoma skin carcinoma insitu carcinoma uterine cervix , provide adequately treat )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>elderly</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>target therapy</keyword>
	<keyword>combination therapy</keyword>
	<keyword>sequential therapy</keyword>
	<keyword>randomize phase II</keyword>
	<keyword>one year survival</keyword>
</DOC>